US equities |
NVDA $233.95 ▲+1.34% MU $1,074.89 ▼-2.05% TSLA $370.59 ▲+4.65% SPCX $158.96 ▲+7.35% SNDK $1,719.99 ▼-3.79% AMD $633.91 ▲+2.95% STX $848.99 ▼-10.21% INTC $119.33 ▼-0.56%
FinancialContent

Articles published by Arcturus Therapeutics

News headline image
Arcturus Therapeutics to Host Key Opinion Leader (KOL) Presentation of ARCT-810 Phase 2 Interim Data for Ornithine Transcarbamylase (OTC) Deficiency
From Arcturus Therapeutics
Via Business Wire
Tickers ARCT
News headline image
Arcturus Therapeutics Receives Clearance of an Investigational New Drug Application to U.S. Food and Drug Administration for ARCT-032, an Investigational Inhaled mRNA Therapeutic to Treat Cystic Fibrosis
From Arcturus Therapeutics
Via Business Wire
Tickers ARCT
News headline image
Nature Communications Publishes Pivotal Data Demonstrating Efficacy and Tolerability of CSL and Arcturus Therapeutics’ COVID-19 Vaccine
From Arcturus Therapeutics
Via Business Wire
Tickers ARCT ASX:CSL CSLLY OTC
News headline image
New COVID-19 sa-mRNA Results from CSL and Arcturus Therapeutics Demonstrate Longer Duration of Immunity Compared to Conventional COVID-19 mRNA Vaccine Booster
From Arcturus Therapeutics
Via Business Wire
Tickers ARCT ASX:CSL CSLLY OTC
News headline image
CSL and Arcturus Therapeutics’ ARCT-154 Demonstrates Non-Inferiority to Original Strain and Superior Immunogenicity to Omicron BA.4/5 Variant Compared to First-Generation mRNA Vaccine Booster
From Arcturus Therapeutics
Via Business Wire
Tickers ARCT ASX:CSL CSLLY OTC
News headline image
Arcturus Therapeutics to Attend Upcoming Investor Conferences
From Arcturus Therapeutics
Via Business Wire
Tickers ARCT
News headline image
Arcturus Therapeutics Joint Venture mRNA Manufacturing Partner, ARCALIS, Awarded $115 Million in Grants from the Japanese Government
From Arcturus Therapeutics
Via Business Wire
Tickers ARCT
News headline image
Arcturus Therapeutics to Report First Quarter 2022 Financial Results and Provide Corporate Update on May 9, 2022
From Arcturus Therapeutics
Via Business Wire
Tickers ARCT
News headline image
Arcturus Therapeutics to Report Fourth Quarter and Year-End 2021 Financial Results and Provide Corporate Update on February 28, 2022
From Arcturus Therapeutics
Via Business Wire
Tickers ARCT
News headline image
Arcturus Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Arcturus Therapeutics
Via Business Wire
Tickers ARCT